Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone Neoadjuvant Treatment in High-Risk/Locally Advanced Breast Cancer
NCT05983094Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05983094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983094.